MOLINA ARTURO MD 4

4 · Protagonist Therapeutics, Inc · Filed Mar 27, 2026

AI-generated summary of this filing

Updated Mar 27, 2026

Protagonist (PTGX) CMO Arturo Molina Exercises Options, Sells 15K

What Happened

Arturo Molina, M.D., Chief Medical Officer of Protagonist Therapeutics (PTGX), exercised 15,000 stock options on March 26, 2026 at a strike price of $8.04 per share (cost $120,600) and sold 15,000 shares in an open-market transaction the same day for a weighted average price of $104.79 per share (total proceeds ≈ $1,571,850). The filing also shows a derivative disposition of 15,000 units at $0.00, reflecting the option conversion to shares.

Key Details

Transaction date: 2026-03-26; Form 4 filed 2026-03-27 (timely).
Option exercise: 15,000 shares acquired at $8.04 each = $120,600.
Open-market sale: 15,000 shares sold at weighted avg $104.79 = $1,571,850.
Sale price range: $103.99 to $105.54 (weighted average reported; issuer can provide per-trade breakdown on SEC staff request). (Footnote F1)
Option background: Option grant dated Nov 7, 2022; one quarter vested Nov 7, 2023, remaining three quarters vest monthly through Nov 7, 2026, subject to continued service. (Footnote F2)
Shares owned after the transaction: not stated in the provided excerpt of the Form 4.

Context

This was an exercise of vested options followed by an immediate sale of the resulting shares (common pattern to realize gains and cover exercise costs). Transaction codes: M = option exercise/conversion, S = sale. The report appears timely (filed one day after the transaction).

Form 4

Period: 2026-03-26

Chief Medical Officer

Transactions

Exercise/Conversion
Common Stock
2026-03-26$8.04/sh+15,000$120,600→ 99,115 total
Sale
Common Stock
[F1]
2026-03-26$104.79/sh−15,000$1,571,850→ 84,115 total
Exercise/Conversion
Stock Option (right to buy)
[F2]
2026-03-26−15,000→ 50,971 total
Exercise: $8.04Exp: 2032-11-15→ Common Stock (15,000 underlying)

Footnotes (2)

[F1]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $103.99 to $105.54. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
[F2]The stock option was granted to the Reporting Person on November 7, 2022, one quarter vested on November 7, 2023 and the remaining three quarters vest in equal monthly installments through November 7, 2026, subject to the Reporting Person's continuous service to the Issuer.

Signature

/s/ Matthew Gosling, Attorney-in-Fact for Arturo Molina, MD|2026-03-27

1 file